# Efficacy and Safety of Oral Neomycin for the Decolonization of Carbapenem-Resistant Enterobacterales: An Open-Label Randomized Controlled Trial

**Authors:** Lalita Tancharoen, Ananya Srisomnuek, Surapee Tiengrim, Narisara Thamthaweechok, Teerawit Tangkorskul, Visanu Thamlikitkul

PMC · DOI: 10.3390/antibiotics13080781 · Antibiotics · 2024-08-20

## TL;DR

A study tested oral neomycin to reduce gut colonization of antibiotic-resistant bacteria, finding short-term effectiveness but temporary results.

## Contribution

This is the first open-label randomized trial evaluating neomycin's efficacy for decolonizing carbapenem-resistant Enterobacterales in humans.

## Key findings

- Neomycin reduced CRE colonization by 42.8–53.8% by day 7, compared to controls.
- CRE colonization rates in the neomycin group rebounded to match controls by day 14.
- Neomycin caused only mild and temporary gastrointestinal side effects.

## Abstract

Background: Patients with carbapenem-resistant Enterobacterales (CRE) in the gastrointestinal (GI) tract are at risk for subsequent infections and transmission, necessitating contact precautions. Neomycin has shown in vitro activity against CRE in 66–85% of isolates. This study evaluated the efficacy and safety of neomycin for CRE decolonization. Methods: In this open-label randomized controlled trial, stool/rectal swab samples from high-risk patients were collected and tested for CRE colonization in the GI tract. Patients who had CRE and met eligible criteria were divided into a neomycin group (n = 26; treated with 4.2 g/day neomycin for 5 days) and a control group (n = 26). CRE detection in stool/rectal swabs was performed on days 7 ± 2 and 14 ± 2. Results: The two groups’ baseline characteristics were similar. CRE presence on day 7 ± 2 was significantly lower in the neomycin group (46.2%) than in the control group (80.8%, p = 0.01). Efficacy of neomycin (4.2 g/day for 5 days) for CRE decolonization was 42.8–53.8% by day 7. By day 14 ± 2, the CRE rate in the neomycin group had risen to align with the control group’s rate (73.1% vs. 61.5%, p = 0.56). The neomycin group experienced mild, temporary, gastrointestinal side-effects. Conclusions: Neomycin effectively reduced CRE colonization on day 7 ± 2, but its impact waned by day 14 ± 2. This suggests that neomycin dosage was too low and the duration of treatment was too short for lasting CRE decolonization.

## Linked entities

- **Chemicals:** neomycin (PubChem CID 8378)

## Full-text entities

- **Diseases:** infections (MESH:D007239), gastrointestinal side-effects (MESH:D064420)
- **Chemicals:** Carbapenem (MESH:D015780), Neomycin (MESH:D009355)
- **Species:** Homo sapiens (human, species) [taxon 9606], Enterobacterales (order) [taxon 91347]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11351571/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11351571/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC11351571/full.md

---
Source: https://tomesphere.com/paper/PMC11351571